Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG547

—

babd6d5c-2a9f-51a8-931f-802756ba5123

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.648
  • INTERFERON_GAMMA_RESPONSE+0.462
  • E2F_TARGETS+0.366
  • ALLOGRAFT_REJECTION+0.352
  • G2M_CHECKPOINT+0.329
  • OXIDATIVE_PHOSPHORYLATION+0.292
  • PROTEIN_SECRETION+0.286
  • MYC_TARGETS_V1+0.284
  • MTORC1_SIGNALING+0.265
  • CHOLESTEROL_HOMEOSTASIS+0.242

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.329
  • HYPOXIA-0.287
  • ANGIOGENESIS-0.266
  • HEDGEHOG_SIGNALING-0.264
  • COAGULATION-0.225
  • MYOGENESIS-0.225
  • TGF_BETA_SIGNALING-0.206
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.171
  • UV_RESPONSE_UP-0.168
  • WNT_BETA_CATENIN_SIGNALING-0.157

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CQ-6219-01A-11R-1915-07
head-neck@1
——0.809
288302
medullo-epn-umap@date-based
EPNSupratentorial EPN0.803
3BS_W80TJC27
medullo-epn-umap@date-based
EPNSupratentorial EPN0.794
4SRR12202424
bladder-landscape@3
——0.782
5TCGA-DK-A1A6-01A-11R-A13Y-07
bladder-landscape@3
——0.782
6TCGA-A8-A09G-01A-21R-A00Z-07
breast-umap@18
—C0.781
7TCGA-AO-A03O-01A-11R-A00Z-07
breast-umap@18
—C0.779
8BS_CZ3ER8DY
medullo-epn-umap@date-based
EPNSupratentorial EPN0.777
9b652254e-228b-40d4-be79-536ad87dad69
melanoma-umap@29
——0.776
10SRR26320066
bladder-landscape@3
——0.776

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.648Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.462Idelalisib— uncovered
E2F_TARGETS0.366Inavolisib— uncovered
ALLOGRAFT_REJECTION0.352Idelalisib— uncovered
G2M_CHECKPOINT0.329Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.292Remibrutinib— uncovered
PROTEIN_SECRETION0.286Remibrutinib— uncovered
MYC_TARGETS_V10.284Inavolisib— uncovered
MTORC1_SIGNALING0.265Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.242Remibrutinib— uncovered
MITOTIC_SPINDLE0.220Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.218Inavolisib— uncovered
DNA_REPAIR0.193Idelalisib— uncovered
NOTCH_SIGNALING0.164Inavolisib— uncovered
ANDROGEN_RESPONSE0.143Inavolisib— uncovered
ADIPOGENESIS0.130Inavolisib— uncovered
PEROXISOME0.119Idelalisib— uncovered
HEME_METABOLISM0.116Temsirolimus— uncovered
PANCREAS_BETA_CELLS0.095Cobimetinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.094Idelalisib— uncovered